PharmNovo aims to change the lives of people suffering from chronic pain
Patients with neuropathic pain are a growing population facing increasingly challenging conditions. Finding a safe and effective way to help those patients has always been the Holy Grail to PharmNovo’s founder Bengt von Mentzer. PharmNovo’s promising drug candidate PN6047 will shortly be entering phase II proof-of-concept studies. »
